ICYMI: Top Tweet in January Clinical trials generally fail in Sjögren's syndrome; but now a study shows that a biologic B cell inhibitor, ianalumab, met its primary endpoint with a dose-related decrease in disease activity (measured by ESSDAI) at week 24. https://t.co/SLn2qs8En4 https://t.co/nMOUm2C9It